Evangelos Boultadakis

Dr. Evangelos Boultadakis

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 August 2011 in Mediators of Inflammation
Verified
Journal Article
Open access
PDF file
EBEvangelos Boultadakis
Evangelos Boultadakis
VSVasileios S. Skouras
Vasileios S. Skouras
DMDemosthènes A. Makris
Demosthènes A. Makris
ADAggeliki Damianaki
Aggeliki Damianaki
DNDimitrios J. Nikoulis
Dimitrios J. Nikoulis
KGKonstantinos Gourgoulianis
Konstantinos Gourgoulianis
Study objectives. To assess serum amyloid alpha (SAA) pleural fluid levels in parapneumonic effusion (PPE) and to investigate SAA diagnostic performance in PPE diagnosis and outcome.Methods. We studied prospectively 57 consecutive patients with PPE (empyema (EMP), complicated (CPE), and uncomplicated parapneumonic effusion (UPE)). SAA, CRP, TNF-α, IL-1β, and IL-6 levels were evaluated in serum and pleural fluid at baseline. Patients were followed for 6-months to detect pleural thickening/loculations.Results. Pleural SAA levels (mg/dL) median(IQR) were significantly higher in CPE compared to UPE (P<0.04); CRP levels were higher in EMP and CPE compared to UPE (P<0.01). There was no significant difference between IL-1β, IL-6, TNF-α level in different PPE forms. No significant association between SAA levels and 6-month outcome was found. At 6-months, patients with no evidence of loculations/thickening had significantly higher pleural fluid pH, glucose levels (P=0.03), lower LDH (P=0.005), IL-1β levels (P=0.001) compared to patients who presented pleural loculations/thickening.Conclusions. SAA is increased in complicated PPE, and it might be useful as a biomarker for UPE and CPE diagnosis. SAA levels did not demonstrate considerable diagnostic performance in identifying patients who develop pleural thickening/loculations after a PPE.

Verified
Journal Article
Open access
PDF file
VAVASILIKI ANDROUTSOPOULOU
VASILIKI ANDROUTSOPOULOU
PZProkopis-Andreas Zotos
Prokopis-Andreas Zotos
Andrew XanthopoulosAndrew Xanthopoulos
Andrew Xanthopoulos
EBEvangelos Boultadakis
Evangelos Boultadakis
Dimitrios E. MagouliotisDimitrios E. Magouliotis
Dimitrios E. Magouliotis
Thanos AthanasiouThanos Athanasiou
Thanos Athanasiou
Aortic valve diseases affect a significant percentage of the population, and with the extension of survival expectancy, they are expected to increase furthermore. Surgical treatment of aortic valve diseases mainly includes valve replacement and, rarely, its repair. The technology of both surgical and transcatheter valves is evolving, and new prosthetic valves with improved characteristics are available, e.g., longer lifespan, faster implantation, better hemodynamic performance with better effective orifice area, suitable for small aortic annuli, etc. Minimally invasive surgical techniques are constantly evolving and spreading. New access sites are used for transcatheter valve implantation. The Heart Team determines the most appropriate intervention for each patient based on their anatomical and clinical profiles, aiming to optimize long-term outcomes.

17 September 2025 in Heart, Lung and Circulation
Verified
Journal Article
Closed access
IZIoannis Zoupas
Ioannis Zoupas
ASAndreas Sarantopoulos
Andreas Sarantopoulos
NSNikolaos Schizas
Nikolaos Schizas
EBEvangelos Boultadakis
Evangelos Boultadakis
IKIoannis Koukis
Ioannis Koukis
DIDimitrios C. Iliopoulos
Dimitrios C. Iliopoulos